Biotech
-
Eli Lilly Grows Revenue 39% After 15% GLP-1 Price Cut and Raises Full-Year Outlook
Volume growth offset a 15% price drop, driving 39% revenue rise and funding R&D for next-gen therapies.
-
CAR-T Market Forecast Nearly Doubles to 2031 While Labels Carry Cancer Warnings
ISLAMABAD, July 7 — The global market for CAR-T cell therapy, a personalized cancer treatment that reprograms a…
-
ADMA Biologics Faces Securities Class Action Over Alleged Channel Stuffing
NEW YORK — A securities fraud class action filed against ADMA Biologics has placed the company’s sales tactics…
-
Record Drug Deals Signal China’s Rise in Global Pharma
BEIJING, July 13 — China’s pharmaceutical industry has just closed the books on a record-breaking first half of…
-
Nasdaq-Listed Conexeu Sciences Opens Lab to Scale Aesthetics Platform
NEW YORK — The press release landed July 1. A Nasdaq-traded company, Conexeu Sciences Inc., said it opened…
-
Conexeu Sciences Opens Lab but Withholds Key Details on Facility
One press release. One Nasdaq-listed company. One new laboratory. But the announcement from Conexeu Sciences Inc., issued July…
-
Tyra Biosciences Shares Fall 30% After Phase 2 Dabogratinib Bladder Cancer Data
NEW YORK, June 30 — Tyra Biosciences, Inc. (NASDAQ:TYRA) made the cut in a recent roundup of the…
-
Sagimet Biosciences Joins Russell 2000 and 3000 Indexes in Annual Reconstitution
Index additions can feel like a rubber-stamp affair. A company hits a market-cap threshold, a committee runs the…
-
ADMA Biologics Faces Federal Lawsuit Over Alleged Revenue Inflation
A federal securities fraud lawsuit now directly implicates thousands of ordinary investors who bought stock in ADMA Biologics,…
-
Ipsen Buys Kartos Therapeutics for $450 Million to Add Myelofibrosis Drug Navtemadlin
PARIS, June 29 — Ipsen has signed a definitive agreement to acquire Kartos Therapeutics, a move that bolsters…
-
GALT’s Best Day in a Year: FDA Opens the Door to Belapectin’s Decisive Trial
Biotech investors are waking up to a different market this morning. The usual cautious positioning has given way…
-
Ernexa Therapeutics Begins GMP Manufacturing for Cell Therapy ERNA-101
CAMBRIDGE, Mass. — The road from lab bench to bedside is littered with failures. Most drug candidates never…
-
Ernexa Therapeutics Targets Q3 2026 IND Filing for ERNA-101
CAMBRIDGE, Mass., June 17 — Ernexa Therapeutics Inc. has announced significant progress in the development of its lead…
-
FibroGen Takes the Kyntra Bio Name and a New Nasdaq Ticker
Kyntra Bio, Inc., formerly known as FibroGen, Inc., a biopharmaceutical company based in San Francisco, California, has undergone…
-
BeiGene Rebrands as BeOne Medicines in Oncology Push
Cambridge, Massachusetts, November 20, 2024 — cyberinktimes.com — A global oncology company that began with two founders in…
-
AbbVie Acquires ImmunoGen for $10.1 Billion in Biotech Deal
In an innovative stride for the biotech sector, on the 15th of November, 2023, AbbVie Corporation, a leading…
-
Erasca Founder Jonathan Lim Takes His Ignyta Playbook to RAS Cancer Drugs
SAN DIEGO, July 15 — When Jonathan E. Lim founded Erasca in 2018, he was already carrying a…
-
Seoul Says Yes: Anixa’s Breast Cancer Patent and the Long Wait for a Vaccine
Dr. Amina Karimova, a patent law specialist at the Tashkent Institute of Biotechnology, has been tracking Anixa Biosciences…
Most read
-
CoreWeave’s GPU-backed debt fuels AI growth but triggers bond market fears
-
Wall Street Reassesses AI Valuations as Market Wobbles Highlight Debt Risks
-
Nidec Machine Tool Launches MVR-5X Double-Column Five-Axis Milling Machine
-
Anthropic Delays IPO as Gartner Data Shows AI Costs Outrunning Projected Revenue
-
AppLovin Hit With Securities Class Action Over Alleged Misstatements on AI Model Strength
-
Asian Stocks Mixed as Investors Weigh Nvidia Fallout and Leadership Exit
-
Tether Gold’s KPMG Audit Sets New Verification Standard for Tokenized Commodities
-
US Market Volatility Persists as Investors Debate if Tech Selloff Has Bottomed
-
Nvidia shares fall 3% as traders open $9.1M short on Huang spy scandal
-
Japan Tobacco’s 272-yen dividend at risk as Putin seizes Russian assets, stock crashes 19%
-
How European Airlines Use Financial Hedging to Weather Surging Fuel Costs
-
How the Century-Old Jones Act Shapes Fuel Costs and Regional Shipping in Hawaii
-
How Router Failures and Outdated Tech Triggered the Nationwide FAA Ground Stop
-
Why Soaring Jet Fuel Costs and Surging Demand Mean High Airfares Are Here to Stay
-
Private Equity Takeover of easyJet Risks Higher Fares and Service Cuts
-
Copper Faces Tug-of-War Between Macroeconomic Headwinds and Structural Shortages
-
Inside Archer-Daniels-Midland’s Strategy for Scaling Global Agribusiness
-
How Shifting Macroeconomic Conditions Are Reshaping Global Commodity Market Allocations
-
China’s New Trade Corridors: How State-Backed Buying Bypasses U.S. Commodity Suppliers
-
How Nigeria’s Lithium Factories Could Reshape Africa’s EV Battery Costs and Energy Security